| Literature DB >> 26594153 |
Jens Stepan1, Florian Hladky2, Andrés Uribe3, Florian Holsboer4, Mathias V Schmidt3, Matthias Eder2.
Abstract
Antidepressants (ADs) are used as first-line treatment for most stress-related psychiatric disorders. The alterations in brain circuit dynamics that can arise from stress exposure and underlie therapeutic actions of ADs remain, however, poorly understood. Here, enabled by a recently developed voltage-sensitive dye imaging (VSDI) assay in mouse brain slices, we examined the impact of chronic stress and concentration-dependent effects of eight clinically used ADs (belonging to different chemical/functional classes) on evoked neuronal activity propagations through the hippocampal trisynaptic circuitry (HTC: perforant path → dentate gyrus (DG) → area CA3 → area CA1). Exposure of mice to chronic social defeat stress led to markedly weakened activity propagations ("HTC-Waves"). In contrast, at concentrations in the low micromolar range, all ADs, which were bath applied to slices, caused an amplification of HTC-Waves in CA regions (invariably in area CA1). The fast-acting "antidepressant" ketamine, the mood stabilizer lithium, and brain-derived neurotrophic factor (BDNF) exerted comparable enhancing effects, whereas the antipsychotic haloperidol and the anxiolytic diazepam attenuated HTC-Waves. Collectively, we provide direct experimental evidence that chronic stress can depress neuronal signal flow through the HTC and demonstrate shared opposing effects of ADs. Thus, our study points to a circuit-level mechanism of ADs to counteract stress-induced impairment of hippocampal network function. However, the observed effects of ADs are impossible to depend on enhanced neurogenesis.Entities:
Keywords: activity propagation; antidepressants; hippocampus; imaging; ketamine; stress; trisynaptic circuit; voltage-sensitive dye
Mesh:
Substances:
Year: 2015 PMID: 26594153 PMCID: PMC4635222 DOI: 10.3389/fncir.2015.00070
Source DB: PubMed Journal: Front Neural Circuits ISSN: 1662-5110 Impact factor: 3.492
Figure 1Principle of the HTC-Wave Voltage-Sensitive Dye Imaging (VSDI) assay in mouse hippocampal slices. (A,B) Experimental arrangement used to obtain the data shown in (C) and (D) (modified from Stepan et al., 2012). MF, mossy fiber; PP, perforant path; ROI, region of interest; SC, Schaffer collateral; SL, stratum lucidum; SR, stratum radiatum; Stim, extracellular electrical stimulation; TA, temporoammonic pathway. (C) VSDI filmstrip of a submaximal HTC-Wave evoked by theta-frequency (5 Hz) electrical stimulation of the perforant path (stimulus 5). Only selected imaging frames are shown (sampling time was 2.2 ms). Warmer colors represent higher values of the fractional change in fluorescence (ΔF/F) of the voltage-sensitive dye and, thus, stronger neuronal activity. For the appearance of maximal (saturated) HTC-Waves see Stepan et al. (2012). (D) Depiction of ROI-extracted fast, depolarization-mediated imaging signals (FDSs), which reflect neuronal action potentials and glutamatergic excitatory postsynaptic potentials (EPSPs). Note the typically increasing CA3 signals and the delayed occurrence of CA1-FDSs, which predominantly derive from frequency facilitation of neurotransmission at mossy fiber synapses onto CA3 pyramidal neurons (cf., supplementary movie in Stepan et al., 2012).
Figure 3Time course of fluoxetine effects (A) and concentration-dependent impact of amitriptyline, clomipramine, fluoxetine, citalopram, fluvoxamine, venlafaxine, tianeptine, and tranylcypromine (B) on HTC-Waves in slices from non-stressed mice. (A) As done with all other drugs probed, fluoxetine (10 μM) was bath applied to slices (n = 7) if baseline recording of HTC-Waves was stable over 20 min. Subsequent recording time was always 40 min. Data were normalized to mean baseline FDS amplitude values. (B) For statistical analysis, one-way ANOVAs were applied to the DG-, CA3-, and CA1-FDS data sets (% change in FDS amplitude, minutes 42–60 vs. minutes 0–18 of VSDI recording (A)) covering the whole range of concentrations probed. Due to its very strong effects at 5 and 10 μM, tianeptine was no longer tested at 15 and 20 μM. DG: fluvoxamine: F(6,50) = 4.2, p = 0.002; 10 μM, t(7) = −5.3, p = 0.001; venlafaxine: F(6,52) = 2.7, p = 0.021; 1 μM, t(8) = −3.1, p = 0.014; 10 μM, t(8) = −9.5, p < 0.001; CA3: fluoxetine: F(6,47) = 2.5, p = 0.033; 10 μM, t(6) = 3.5, p = 0.013; 15 μM, t(6) = 3.4, p = 0.013; 20 μM, t(7) = 3.4, p = 0.011; venlafaxine: F(6,52) = 4.2, p = 0.002; 0.5 μM, t(9) = 2.6, p = 0.027; 5 μM, t(7) = 3.0, p = 0.019; tianeptine: F(4,30) = 8.8, p < 0.001; 0.5 μM, t(6) = 2.8, p = 0.031; 1 μM, t(6) = 2.6, p = 0.043; 5 μM, t(6) = 4.0, p = 0.007; 10 μM, t(6) = 4.4, p = 0.005; tranylcypromine: F(6,56) = 3.7, p = 0.004; 0.1 μM, t(7) = −4.6, p = 0.002; CA1: amitriptyline: F(6,46) = 4.2, p = 0.002; 10 μM, t(6) = 3.3, p = 0.016; clomipramine: F(6,59) = 2.8, p = 0.02; 15 μM, t(8) = 2.8, p = 0.023; fluoxetine: F(6,47) = 4.6, p < 0.001; 1 μM, t(7) = 2.4, p = 0.047; 5 μM, t(7) = 3.3, p = 0.013; 10 μM, t(6) = 5.2, p = 0.002; 15 μM, t(6) = 4.2, p = 0.006; 20 μM, t(7) = 3.4, p = 0.01; citalopram: F(6,51) = 2.3, p = 0.049; 5 μM, t(9) = 3.7, p = 0.005; 15 μM, t(7) = 4.9, p = 0.002; fluvoxamine: F(6,50) = 5.9, p < 0.001; 10 μM, t(7) = 2.9, p = 0.023; 15 μM, t(7) = 3.1, p = 0.017; 20 μM, t(8) = 3.2, p = 0.016; venlafaxine: F(6,52) = 4.8, p < 0.001; 0.5 μM, t(9) = 4.6, p = 0.001; 5 μM, t(7) = 3.0, p = 0.019; 15 μM, t(6) = 2.9, p = 0.014; 20 μM, t(7) = 3.4, p = 0.022; tianeptine: F(4,30) = 11.2, p < 0.001; 0.5 μM, t(6) = 3.6, p = 0.012; 1 μM, t(6) = 5.8, p = 0.001; 5 μM, t(6) = 4.6, p = 0.004; 10 μM, t(6) = 4.6, p = 0.004; tranylcypromine: H(6) = 18.6, p = 0.005 (Kruskal-Wallis ANOVA on ranks); 0.1 μM, t(7) = −3.6, p = 0.008; 10 μM, t(7) = 4.4, p = 0.003. Number of experiments (slices) for 0.1, 0.5, 1, 5, 10, 15, and 20 μM: amitriptyline: n = 8, 8, 8, 7, 7, 7, and 8; clomipramine: n = 9, 12, 10, 10, 8, 9, and 8; fluoxetine: n = 8, 8, 8, 8, 7, 7, and 8; citalopram: n = 8, 9, 8, 10, 8, 8, and 7; fluvoxamine: n = 8, 8, 8, 8, 8, 8, and 9; venlafaxine: n = 8, 10, 9, 8, 9, 7, and 8; tianeptine: n = 7, 7, 7, 7, and 7; tranylcypromine: n = 8, 10, 8, 8, 8, 13, and 8. For each pharmacological condition, a maximum number of two slices per animal was used. (C) Relative change in CA3/CA1 activity ratios in the presence of 10 μM amitriptyline (a), 15 μM clomipramine (b), 20 μM fluoxetine (c), 15 μM citalopram (d), 20 μM fluvoxamine (e), 5 μM venlafaxine (f), 5 μM tianeptine (g), and 10 μM tranylcypromine (h; amitriptyline: t(6) = −5.4, p = 0.002; clomipramine: t(8) = −7.8, p < 0.001; fluoxetine: t(7) = −6.1, p < 0.001; citalopram: t(7) = −5.1, p = 0.001; fluvoxamine: t(8) = −5.8, p < 0.001; venlafaxine: t(7) = −3.9, p = 0.008; tianeptine: t(6) = −8.6, p < 0.001; one-sample t-tests). *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 2Exposure of mice to chronic social defeat stress causes markedly weakened HTC-Waves. (A) Data from body weight measurements (body weight gain during stress/non-stress exposure; stress (n = 7) vs. control (n = 6): t(11) = −4.6, p < 0.001; two-tailed unpaired t-test). (B) Representative VSDI recording traces for control and stress conditions. For both recording sequences, the intensity of perforant path stimulation (15 pulses at 5 Hz) was adjusted such that the first DG-FDS had an amplitude of 0.45% ΔF/F. (C) Quantification of VSDI measurements (n = 6 animals/18 slices for the control group and n = 7 animals/19 slices for the stress group; VSDI measures obtained from 2–3 slices per animal were averaged, leading to n values of 6 and 7 for the control and stress group, respectively; stress vs. control: CA3: t(11) = −5.0, p < 0.001; CA1: t(11) = −5.7, p < 0.001; two-tailed unpaired t-tests). For a detailed description of how the measure “Mean FDS amplitude” was calculated see “Materials and Methods”. (D) Relationships between mean CA1-FDS amplitude and duration of stress/non-stress exposure (p values were determined by linear regression analyses). (E) In slices from both control and stressed mice, the amplitude of CA1-FDSs linearly increased with the amplitude of CA3-FDSs. Data were obtained by averaging the CA1- and CA3-FDS amplitude values for electrical stimulus 1, 2, 3, …, 15 over the 18/19 experiments performed in control/stressed mice, in which the amplitude of the first DG-FDS was adjusted to ~0.45% ΔF/F. (F) The typical increase in CA3- and CA1-FDSs during 5 Hz perforant path stimulation is much weaker in slices from stressed animals. (G) CA3/CA1 activity ratios for the experiments conducted in control/stressed mice, in which the amplitude of the first DG-FDS was adjusted to 0.45% ΔF/F (stress vs. control: t(11) = 3.5, p = 0.005; two-tailed unpaired t-test). **p < 0.01, ***p < 0.001; n.s., not statistically significant.
Figure 4Impact of lithium, BDNF, ketamine, haloperidol, and diazepam on HTC-Waves in slices from non-stressed mice. (A) For statistical analysis, one-sample t-tests were used (lithium (n = 7 slices for 0.5 and 1 mM): CA1: 0.5 mM, t(6) = 2.5, p = 0.045; 1 mM, t(6) = 7.5, p < 0.001; BDNF (n = 8 slices): CA3: t(7) = 3.6, p = 0.008; CA1: t(7) = 3.4, p = 0.011; ketamine (n = 8 slices): CA3: t(7) = 4.9, p = 0.002; CA1: t(7) = 4.2, p = 0.004). (B) Relative change in CA3/CA1 activity ratios in the presence of 1 mM lithium (a), 0.4 nM BDNF (b), 20 μM ketamine (c), 20 μM haloperidol (d), and 1 μM diazepam (e; lithium: t(6) = −9.7, p < 0.001; BDNF: t(7) = −3.5, p = 0.01; ketamine: t(7) = −3.6, p = 0.009; haloperidol: t(5) = 2.7, p = 0.035; diazepam: t(5) = 3.3, p = 0.029; one-sample t-tests). (C) Statistical evaluation of haloperidol effects was performed as done for ADs. For diazepam effects, the one-sample t-test was used (haloperidol: DG: F(6,43) = 17.8, p < 0.001; 10 μM, t(7) = −4.3, p = 0.003; 15 μM, t(5) = −4.8, p = 0.005; 20 μM, t(5) = −10.1, p < 0.001; CA3: F(6,43) = 4.3, p = 0.002; 10 μM, t(7) = −3.7, p = 0.007; 15 μM, t(5) = −3.0, p = 0.028; 20 μM, t(5) = −8.7, p < 0.001; CA1: F(6,43) = 3.6, p = 0.005; 10 μM, t(7) = −3.5, p = 0.01; 15 μM, t(5) = −3.5, p = 0.017; 20 μM, t(5) = −9.0, p < 0.001; number of experiments (slices) for 0.1, 0.5, 1, 5, 10, 15, and 20 μM: n = 8, 8, 6, 8, 8, 6, and 6; diazepam (n = 7 slices for 0.1 μM and n = 6 slices for 1 μM): DG: 1 μM, t(5) = −4.1, p = 0.009; CA3: 0.1 μM, t(6) = −4.9, p = 0.003; 1 μM, t(5) = −7.8, p < 0.001; CA1: 0.1 μM, t(6) = −5.7, p = 0.001; 1 μM, t(5) = −8.4, p < 0.001). For each pharmacological condition, a maximum number of two slices per animal was used. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5Enhancing effects of fluoxetine on HTC-Waves occur in slices from chronically stressed mice and are prevented by the TrkB receptor antagonist ANA-12. For group comparisons, two-tailed unpaired t-tests were used. For statistical analyses of fluoxetine effects in slices (n = 8) from stressed mice and ANA-12-treated slices (n = 11), one-sample t-tests were employed (stress: CA3: t(7) = 2.4, p = 0.048; CA1: t(7) = 4.7, p = 0.002; ANA-12: DG: t(10) = −3.8, p = 0.003; for statistics of fluoxetine effects in naive slices see Figure 3; ANA-12 vs. naive: CA3: t(16) = −2.8, p = 0.012; CA1: t(16) = −3.4, p = 0.003). For each pharmacological condition, a maximum number of two slices per animal was used. *p < 0.05, **p < 0.01; n.s., not statistically significant.